Early trial tests cell injection to repair diabetic kidneys
NCT ID NCT07275788
Summary
This early-stage study is testing the safety of an experimental cell therapy called REGEND003 in people with type 2 diabetes and chronic kidney disease. The therapy involves injecting human kidney progenitor cells directly into the kidney, with the goal of repairing kidney damage. Researchers will enroll about 15 participants to see if the treatment is safe and to look for early signs that it might improve kidney function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) AND CHRONIC KIDNEY DISEASE (CKD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Tongji Hospital
RECRUITINGShanghai, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.